Atea Pharmaceuticals, Inc.

Informe acción NasdaqGS:AVIR

Capitalización de mercado: US$290.4m

Salud financiera de hoja de balance de Atea Pharmaceuticals

Salud financiera controles de criterios 6/6

Atea Pharmaceuticals tiene un patrimonio de los accionistas total de $476.5M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $510.4M y $33.9M respectivamente.

Información clave

0%

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de interesesn/a
EfectivoUS$502.21m
PatrimonioUS$476.47m
Total pasivoUS$33.91m
Activos totalesUS$510.38m

Actualizaciones recientes sobre salud financiera

Recent updates

Atea wins FDA Fast Track status for dengue treatment

Sep 26

Atea Pharmaceuticals Q2 2022 Earnings Preview

Aug 08

Atea Pharmaceuticals, Inc.'s (NASDAQ:AVIR) Shares Not Telling The Full Story

May 13
Atea Pharmaceuticals, Inc.'s (NASDAQ:AVIR) Shares Not Telling The Full Story

Analysts Just Shaved Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Forecasts Dramatically

Jan 05
Analysts Just Shaved Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Forecasts Dramatically

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Analysts Just Slashed Next Year's Estimates

Nov 25
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Analysts Just Slashed Next Year's Estimates

A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)

Oct 24
A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)

A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)

Oct 24
A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)

Atea Pharmaceuticals' COVID Antiviral Trial Failure Hands Initiative To Merck's Molnupiravir

Oct 20

U.S. to invest more than $3B to boost development of COVID-19 antiviral drugs

Jun 17

Atea Pharmaceuticals, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

May 15
Atea Pharmaceuticals, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

Market Sentiment Around Loss-Making Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

May 13
Market Sentiment Around Loss-Making Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

Growth Investors: Industry Analysts Just Upgraded Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Revenue Forecasts By 73%

Apr 08
Growth Investors: Industry Analysts Just Upgraded Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Revenue Forecasts By 73%

Atea Pharmaceuticals (NASDAQ:AVIR) Is In A Strong Position To Grow Its Business

Mar 06
Atea Pharmaceuticals (NASDAQ:AVIR) Is In A Strong Position To Grow Its Business

Need To Know: Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Insiders Have Been Buying Shares

Jan 30
Need To Know: Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Insiders Have Been Buying Shares

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($506.4M) de AVIR superan a sus pasivos a corto plazo ($26.6M).

Pasivo a largo plazo: Los activos a corto plazo de AVIR ($506.4M) superan a sus pasivos a largo plazo ($7.3M).


Historial y análisis de deuda-patrimonio

Nivel de deuda: AVIR está libre de deudas.

Reducción de la deuda: AVIR no ha tenido ninguna deuda en los últimos 5 años.


Hoja de balance


Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: AVIR tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.

Pronóstico de cash runway: AVIR dispone de suficiente cash runway para 2.2 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 35.9% cada año.


Descubre empresas con salud financiera